ArticleAnnals of internal medicine2022
Race, Genotype, and Azathioprine Discontinuation : A Cohort Study.
Article in Annals of internal medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- Association between genetically predicted expression of TPMT and azathioprine adverse events.BMC pharmacology & toxicology · 2026Article
- Exploring the effect of Duffy status on patients with breast cancer receiving cyclin-dependent kinase 4/6 inhibitors.Breast cancer research and treatment · 2025Article
- Article
- Assessing long-term pleiotropic effects of potential novel triglyceride-lowering medications using variants identified by Mendelian randomization.medRxiv : the preprint server for health sciences · 2025Article
- SLCO1B1 Functional Variants, Bilirubin, Statin-Induced Myotoxicity, and Recent Sub-Saharan African Ancestry: A Precision Medicine Health Equity Study.Clinical pharmacology and therapeutics · 2025Article
- PTPN2 and Leukopenia in Individuals With Normal TPMT and NUDT15 Metabolizer Status Taking Azathioprine.Clinical and translational science · 2025Article
- Characterization of the phenotypic consequences of the Duffy-null genotype.Blood advances · 2025Article
- Lupus and other autoimmune diseases: Epidemiology in the population of African ancestry and diagnostic and management challenges in Africa.The journal of allergy and clinical immunology. Global · 2024Review
- Navigating Therapeutic Challenges of Pyoderma Gangrenosum in Felty's Syndrome: A Case Report and Literature Review.Cureus · 2024Article
- Using electronic health records for clinical pharmacology research: Challenges and considerations.Clinical and translational science · 2024Review
- Clinical associations with a polygenic predisposition to benign lower white blood cell counts.Nature communications · 2024Article
- Pharmacogenetic testing and monitoring of complete blood counts among Veterans newly prescribed thiopurine treatments: a retrospective cohort study.Journal of pharmaceutical policy and practice · 2023Article
- Article
- Leveraging our common African origins to understand human evolution and health.Cell genomics · 2023Article
- Absolute neutrophil count by Duffy status among healthy Black and African American adults.Blood advances · 2023Article
- White blood cell ranges and frequency of neutropenia by Duffy genotype status.Blood advances · 2023Article
- Prospects for targeting ACKR1 in cancer and other diseases.Frontiers in immunology · 2023Review
- Eliminating Algorithmic Racial Bias in Clinical Decision Support Algorithms: Use Cases from the Veterans Health Administration.Health equity · 2023Article
- Ancestry,Lupus science & medicine · 2022Article
Corrections and comments
- Commented on by
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThiopurines are an important class of immunosuppressants despite their risk for hematopoietic toxicity and narrow therapeutic indices. Benign neutropenia related to an
objectiveTo test whether rs2814778-CC was associated with azathioprine discontinuation attributed to hematopoietic toxicity and lower thiopurine dosing.
designRetrospective cohort study.
settingTwo tertiary care centers. PATIENTS: Thiopurine users with White or Black race. MEASUREMENTS: Azathioprine discontinuation attributed to hematopoietic toxicity. Secondary outcomes included weight-adjusted final dose, leukocyte count, and change in leukocyte count.
resultsThe rate of azathioprine discontinuation attributed to hematopoietic toxicity was 3.92 per 100 person-years among patients with the CC genotype ( LIMITATIONS: Unmeasured confounding; data limited to tertiary centers.
conclusionPatients with the CC genotype had higher risk for azathioprine discontinuation attributed to hematopoietic toxicity and lower thiopurine doses. Genotype was associated with those risks, even after adjustment for race. PRIMARY FUNDING SOURCE: National Institutes of Health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.